Skip to main content
SpringerLink
Log in

Role of IL-17 and IL-17 Family Cytokines on Tumor Development

  • Chapter
  • First Online:
IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity

Part of the book series: Progress in Inflammation Research ((PIR))

  • 1635 Accesses

Abstract

Anticancer immune responses restrain tumor progression, but persistent immune activation can induce chronic inflammation that contributes to tumor development. The IL-17 family of cytokines comprises six family members (IL-17A to IL-17F) that all contribute to tissue inflammation. Interleukin-17A (IL-17A), the original member of this family, is also the signature cytokine of the recently identified proinflammatory T helper 17 (Th17) cell subset that has been shown to contribute to autoimmunity. Despite their well-characterized proinflammatory functions in vivo, the role of IL-17 cytokine family members on tumor progression remains highly controversial. In this chapter, we review the latest findings on the functions of IL-17 family members in cancer and discuss the potential of these molecules as therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  2. Van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536

    Article  Google Scholar 

  3. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE et al (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822–827

    Article  PubMed  CAS  Google Scholar 

  4. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102–106

    Article  PubMed  CAS  Google Scholar 

  5. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563

    Article  PubMed  CAS  Google Scholar 

  6. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA (2008) Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322:1861–1865

    Article  PubMed  CAS  Google Scholar 

  7. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375–379

    Article  PubMed  CAS  Google Scholar 

  8. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382–1397

    Article  PubMed  CAS  Google Scholar 

  9. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37

    Article  PubMed  Google Scholar 

  10. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998

    Article  PubMed  CAS  Google Scholar 

  11. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907

    Article  PubMed  CAS  Google Scholar 

  12. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198:433–442

    Article  PubMed  CAS  Google Scholar 

  13. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K et al (2004) Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114:379–388

    PubMed  CAS  Google Scholar 

  14. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C et al (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214–219

    Article  PubMed  CAS  Google Scholar 

  15. Crowe NY, Smyth MJ, Godfrey DI (2002) A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196:119–127

    Article  PubMed  CAS  Google Scholar 

  16. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111

    Article  PubMed  CAS  Google Scholar 

  17. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059

    Article  PubMed  CAS  Google Scholar 

  18. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 14:141–151

    Article  PubMed  CAS  Google Scholar 

  19. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S et al (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220:47–59

    Article  PubMed  CAS  Google Scholar 

  20. Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16:115–123

    Article  PubMed  CAS  Google Scholar 

  21. Chen Z, O’Shea JJ (2008) Th17 cells: a new fate for differentiating helper T cells. Immunol Res 41:87–102

    Article  PubMed  CAS  Google Scholar 

  22. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357

    PubMed  CAS  Google Scholar 

  23. van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 5:549–553

    Article  PubMed  Google Scholar 

  24. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H (1999) Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101–104

    PubMed  CAS  Google Scholar 

  25. Aarvak T, Chabaud M, Miossec P, Natvig JB (1999) IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162:1246–1251

    PubMed  CAS  Google Scholar 

  26. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD (1998) Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111:645–649

    Article  PubMed  CAS  Google Scholar 

  27. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R (2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237:123–130

    Article  PubMed  CAS  Google Scholar 

  28. Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177

    PubMed  CAS  Google Scholar 

  29. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V et al (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59:3698–3704

    PubMed  CAS  Google Scholar 

  30. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627

    Article  PubMed  CAS  Google Scholar 

  31. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166

    PubMed  CAS  Google Scholar 

  32. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457–1464

    Article  PubMed  CAS  Google Scholar 

  33. Wang L, Yi T, Zhang W, Pardoll DM, Yu H (2010) IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70:10112–10120

    Article  PubMed  CAS  Google Scholar 

  34. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A 107:5540–5544

    Article  PubMed  CAS  Google Scholar 

  35. Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, Pouly S, Murphy AJ, Valenzuela DM, Yancopoulos GD et al (2009) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136:257–267

    Article  PubMed  CAS  Google Scholar 

  36. Chae WJ, Bothwell AL (2011) IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice. Biochem Biophys Res Commun 414:31–36

    Article  PubMed  CAS  Google Scholar 

  37. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263–1271

    Article  PubMed  CAS  Google Scholar 

  38. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50:980–989

    Article  PubMed  CAS  Google Scholar 

  39. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149

    Article  PubMed  CAS  Google Scholar 

  40. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787–798

    Article  PubMed  CAS  Google Scholar 

  41. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K et al (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112:362–373

    Article  PubMed  CAS  Google Scholar 

  42. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ et al (2011) Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35:972–985

    Article  PubMed  CAS  Google Scholar 

  43. Casares N, Pequignot M, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701

    Article  PubMed  CAS  Google Scholar 

  44. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N et al (2011) Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208:491–503

    Article  PubMed  CAS  Google Scholar 

  45. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–1133

    Article  PubMed  CAS  Google Scholar 

  46. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–189

    Article  PubMed  CAS  Google Scholar 

  47. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ (2011) Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71:4809–4820

    Article  PubMed  CAS  Google Scholar 

  48. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331–341

    Article  PubMed  CAS  Google Scholar 

  49. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170–1178

    Article  PubMed  CAS  Google Scholar 

  50. Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, Lee V, Jin H, Wang M, Wright JA et al (2010) IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 59:805–817

    Article  PubMed  CAS  Google Scholar 

  51. Benatar T, Cao MY, Lee Y, Li H, Feng N, Gu X, Lee V, Jin H, Wang M, Der S et al (2008) Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunol Immunother 57:1757–1769

    Article  PubMed  CAS  Google Scholar 

  52. Furuta S, Jeng YM, Zhou L, Huang L, Kuhn I, Bissell MJ, Lee WH (2011) IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med 3:78ra31

    Article  PubMed  Google Scholar 

  53. Sanders AJ, Guo X, Mason MD, Jiang WG (2010) IL-17B can impact on endothelial cellular traits linked to tumour angiogenesis. J Oncol 2010:817375

    Article  PubMed  Google Scholar 

  54. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35:611–621

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are supported by the INSERM-Région-Bourgogne (H.B.), the Ligue Nationale contre le Cancer (F.V.), and the Agence Nationale de la Recherche [ANR-10-PDOC-014-01] (L.A.). Frédérique Végran and Hélène Berger contributed equally to this work.

Author information

Authors and Affiliations

  1. INSERM, U866, 7bd Jeanne d’Arc, Dijon, 21000, France

    Frédérique Végran, Hélène Berger & Dr. Lionel Apetoh

  2. Centre Georges François Leclerc, Dijon, France

    Dr. Lionel Apetoh

Authors
  1. Frédérique Végran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hélène Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Lionel Apetoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lionel Apetoh .

Editor information

Editors and Affiliations

  1. Institut de Transgénose, Labo. d'Immunologie et, CNRS, rue de la Férollerie 3B, Orleans CX 2, 45071, France

    Valérie Quesniaux

  2. Institut de Transgénose, Labo. d'Immunologie et, CNRS, rue de la Férollerie 3B, Orleans CX 2, 45071, France

    Bernhard Ryffel

  3. Novartis Institute for Biomedical, Research (NIBR), Novartis Pharma AG, Basel, 4002, Switzerland

    Franco Padova

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Basel

About this chapter

Cite this chapter

Végran, F., Berger, H., Apetoh, L. (2013). Role of IL-17 and IL-17 Family Cytokines on Tumor Development. In: Quesniaux, V., Ryffel, B., Padova, F. (eds) IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. Progress in Inflammation Research. Springer, Basel. https://doi.org/10.1007/978-3-0348-0522-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-0522-3_16

  • Published:

  • Publisher Name: Springer, Basel

  • Print ISBN: 978-3-0348-0521-6

  • Online ISBN: 978-3-0348-0522-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation